Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;128(3):421-425.
doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.

Tamoxifen evolution

A Howell  1   2   3 , S J Howell  4   5   6
Affiliations
Review

Tamoxifen evolution

A Howell et al. Br J Cancer. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Clemons M, Danson S, Howell A. Tamoxifen (‘Nolvadex’): a review. Cancer Treat Rev. 2002;28:165–80. doi: 10.1016/S0305-7372(02)00036-1. - DOI - PubMed
    1. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–5. doi: 10.1038/bjc.1971.33. - DOI - PMC - PubMed
    1. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16:3439–60. doi: 10.1200/JCO.1998.16.10.3439. - DOI - PubMed
    1. Howell SJ, Johnston SRD, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18:47–66. doi: 10.1016/j.beem.2003.08.002. - DOI - PubMed
    1. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. doi: 10.1016/S0140-6736(03)12342-2. - DOI - PubMed